The dose-limiting side effects are liver damage, lung disease and immunosuppression.<ref name = rh2010/> The most common side effects (occurring in >1% of those treated with it) are, in approximately descending order of frequency:<ref name = MSR/><ref name = AMH/><ref name = TGA>{{cite web|title=PRODUCT INFORMATION ARAVA®|work=TGA eBusiness Services|publisher=sanofi-aventis australia pty ltd|date=7 August 2012|accessdate=11 March 2014|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-05926-3|format=PDF}}</ref><ref name = EMA>{{cite web|title=Arava : EPAR - Product Information|work=European Medicines Agency|publisher=Sanofi-Aventis Deutschland GmbH|date=21 November 2013|accessdate=11 March 2014|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000235/WC500026289.pdf|format=PDF}}</ref><ref name = MS>{{cite web|title=Data Sheet Arava®|work=Medsafe|publisher=sanofi-aventis new zealand limited|date=29 June 2012|accessdate=11 March 2014|url=http://www.medsafe.govt.nz/profs/datasheet/a/aravatab.pdf|format=PDF}}</ref><ref name = DM>{{cite web|title=ARAVA (leflunomide) tablet, film coated [sanofi-aventis U.S. LLC]|work=DailyMed|publisher=sanofi-aventis U.S. LLC|date=November 2012|accessdate=11 March 2014|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=320f63f2-fac3-4aee-aff8-85724e00ef52}}</ref><ref name = EMC>{{cite web|title=Arava 100mg Tablets - Summary of Product Characteristic|work=electronic Medicines Compendium|publisher=SANOFI|date=21 February 2014|accessdate=11 March 2014|url=http://www.medicines.org.uk/emc/medicine/26343/SPC/Arava+100mg+Tablets/}}</ref> diarrhea, respiratory tract infections, hair loss, [[hypertension|high blood pressure]], rash, nausea, bronchitis, headache, abdominal pain, abnormal [[liver function test]]s, back pain, [[dyspepsia|indigestion]], urinary tract infection, dizziness, infection, joint disorder, itchiness, weight loss, loss of appetite, cough, gastroenteritis, [[pharyngitis]], [[stomatitis]], [[tenosynovitis]], vomiting, weakness, allergic reaction, chest pain, dry skin, eczema, [[paraesthesia]], [[pneumonia]], [[rhinitis]], [[synovitis]], [[cholelithiasis]] and [[dyspnoea|shortness of breath]]. Whereas uncommon side effects (occurring in 0.1-1% of those treated with the drug) include:<ref name = AMH/> constipation, [[Oral candidiasis|oral thrush]], [[stomatitis]], taste disturbance, [[thrombocytopenia]] and [[urticaria|hives]]. Rarely (in 0.1% of those treated with it) it can cause:<ref name = AMH/> [[anaphylaxis]], [[angiooedema]], [[anaemia]], [[agranulocytosis]], [[eosinophilia]], [[leucopenia]], [[pancytopenia]], [[vasculitis]], [[toxic epidermal necrolysis]], [[Stevens-Johnson syndrome]], cutaneous [[lupus erythematosus]], severe infection, [[interstitial lung disease]], [[cirrhosis]] and [[liver failure]].

 


 
Though not reported elsewhere, 80 cases of [[interstitial pneumonitis]] involving leflunomide have been reported in Japan between 2003 and 2006. One such case resulting in a death was reported in a 2006 article from Japan and the authors suggest a "an inter-racial difference" for the interstitial pneumonitis.<ref>{{cite journal|last1=Hirabayashi|first1=Yu|title=Leflunomide-Induced Pneumonitis in a Patient with Rheumatoid Arthritis |journal=Internal Medicine|date=2006|volume=45|pages=689–691|issn= 1349-7235 |doi=10.2169/internalmedicine.45.1455|url=http://doi.org/10.2169/internalmedicine.45.1455|display-authors=etal}}</ref>

 

